Abstract: The present invention provides methods of treating skin disorders includes delivering to a mammal a composition containing a compound of formula I, or tautomers thereof, in a regimen, wherein formula I is: and wherein R1–R5 and Q1 are defined as described herein. Specifically, methods for treating acne, hirsutism, and a composition for conditioning the skin are described.
Type:
Grant
Filed:
June 23, 2003
Date of Patent:
October 3, 2006
Assignee:
Wyeth
Inventors:
Andrew Fensome, Diane Deborah Harrison, Richard Craig Winneker
Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazolopyrimidines, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.
Type:
Grant
Filed:
November 12, 2004
Date of Patent:
August 29, 2006
Assignee:
Icagen, Inc.
Inventors:
Robert N. Atkinson, Michael F. Gross, Albert M. van Rhee
Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
Abstract: The invention relates to the use of compound of Formula I in treating patients for inflammatory or neuropathic pain as well as various symptoms of multiple sclerosis
Type:
Grant
Filed:
December 16, 2003
Date of Patent:
May 9, 2006
Assignee:
Aventis Pharmaceuticals Inc.
Inventors:
Bin Zhu, Joseph Wettstein, Margaret A. Petty
Abstract: The present invention is directed to ACE inhibitor-containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.
Type:
Grant
Filed:
April 22, 2002
Date of Patent:
March 21, 2006
Assignee:
Warner-Lambert Company, LLC
Inventors:
Jane Ellen Daniel, Michael Ray Harris, Gerard Clifford Hokanson, Jay Weiss
Abstract: An improved medical treatment and medicine is provided to quickly and safely resolve herpes and other microbial infections. The inexpensive user-friendly medicine can be applied and maintained on the infected region until the physical symptoms of the disease disappears and the patient is comfortable and has a normal appearance. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent. In the preferred form, the medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution.
Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an inhibitor of human epidermal growth factor receptor tyrosine kinase and a cGMP-specific phosphodiesterase inhibitor.
Abstract: The present invention features formulations of indolinones which compounds are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term “ionizable substituted indolinone” includes pyrrole substituted 2-indolinones which, in addition to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compound, are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group. The formulations and the compounds themselves are useful for the treatment of protein kinase related disorders as discussed herein.
Abstract: The present invention relates to indolinones substituted in the 6-position of general formula wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
Type:
Grant
Filed:
April 4, 2002
Date of Patent:
February 22, 2005
Assignee:
Boehringer Ingelheim Pharma KG
Inventors:
Gerald Juergen Roth, Armin Heckel, Thorsten Lehmann-Lintz, Joerg Kley, Frank Hilberg, Jacobus Van Meel
Abstract: The present invention provides a percutaneously applicable preparation containing an antidementia medicament, wherein the antidementia medicament is incorporated a higher alcohol, a lactate of a higher alcohol, an ester of a higher fatty acid and a lower alcohol, or an ester of a fatty acid having 6-18 carbon atoms and propyleneglycol. The present invention also provides a rectum applicable preparation containing an antidementia medicament, wherein the antidementia medicament is incorporated a tiriglyceride of a fatty acid and/or a water-soluble macromolecule.
Abstract: A combination of 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7,-dimethoxy-2-isoquinolinyl)ethyl]pheny]-4-acridinecarboxamide or a salt thereof and paclitaxel and its analogs or derivatives.
Abstract: A pharmaceutical formulation of paclitaxel and polyethoxylated castor oil is disclosed to be relatively acidified to a pH of less than 8.1 and preferably within a pH range of 5 to 7, inclusively. Ethanol is optionally included in the formulation which is adapted for use in a body for the treatment of cancer, A formulation method is disclosed and includes the step of mixing an acid with a carrier material, such as polyethoxylated castor oil, to form a carrier solution after which paclitaxel is added in an amount such that the resulting pH is less than 8.1 and preferably in a pH range of 5 to 7. Ethanol may optionally be slurried with the paclitaxel before mixing with the carrier solution. A variety of acidifying agents, a preferred one being anhydrous citric acid, are described.
Type:
Grant
Filed:
October 4, 2001
Date of Patent:
August 3, 2004
Assignee:
NaPro BioTherapeutics, Inc.
Inventors:
David Carver, Timothy Prout, Hernita Ewald, Robyn Elliott, Paul Handreck
Abstract: Compositions and kits containing a first chemotherapeutic agent that includes arglabin or a derivative thereof and a second chemotherapeutic agent are described. The compositions and kits are effective for treating cancer in a human patient. Methods for suppressing tumor growth in a human and for reducing the immunodepressive effects of chemotherapeutic agents are also described.
Abstract: Compositions and methods of treatment for conditions in humans and animals which have an inflammatory component, are disclosed. The composition comprises a glucosamine component dispersed in a controlled-release matrix system capable of releasing the glucosamine over a designated time period. In another aspect, the invention provides compositions and methods for the treatment of arthritis in humans and animals without adversely effecting glucose regulation.
Type:
Grant
Filed:
August 29, 2000
Date of Patent:
July 27, 2004
Assignee:
Leiner Health Services Corp.
Inventors:
Robert A. Kay, Larry K. Thomas, Beuford A. Bogue
Abstract: A method of altering specificity of cyclooxygenase-inhibiting compounds that have a COOH moiety by changing the various COOH containing compounds, such as indomethacin, into ester derivatives or into secondary amide derivatives.
Abstract: The invention features a method of treating a subject, e.g., a subject having permeability disjunction, which includes administering to the subject peritoneal dialysis fluid which includes an inhibitor of PKC, e.g., an inhibitor of PKC &bgr;. The invention also features an improved peritoneal dialysis fluid and methods of making such dialysis fluid.
Abstract: Disclosed herein are methods foe reducing stimulant dependency or craving, involving administration of a therapeutically-effective amount of a dopamine agonist, such as pramipexole.
Abstract: A method of inhibiting motor hyperactivity in a mammal exhibiting the symptoms of attention deficit-hyperactivity disorder (ADHD) includes administering to a mammal a dopamine D4 receptor-selective antagonist.
Type:
Grant
Filed:
March 12, 2002
Date of Patent:
June 8, 2004
Assignee:
The McLean Hospital Corporation
Inventors:
Ross J. Baldessarini, Kehong Zhang, Frank I. Tarazi
Abstract: The subject of the invention is a fiber-enriched composition for enteral nutrition, characterized in that it comprises 0.5 to 20%, preferably 1 to 10%, and still more preferably 1 to 5% by dry weight of branched maltodextrins having between 15 and 35% of 1→6 glucoside linkages, a reducing sugar content of less than 20%, a polymolecularity index of less than 5 and a number-average molecular mass Mn at most equal to 4500 g/mol.